As GLP-1 Options Multiply, Personalized Care Matters More Than Ever
GLP-1s like semaglutide and tirzepatide have quickly grown in popularity in the U.S. thanks to their ability to help some users manage their weight. Part of that popularity stems…
DO
By Daniel Okafor · Regulatory Correspondent
Oct 15 14:56 ETSource: The State
From the source
Read at thestate.comAs GLP-1 Options Multiply, Personalized Care Matters More Than Ever
GLP-1s like semaglutide and tirzepatide have quickly grown in popularity in the U.S. thanks to their ability to help some users manage their weight. Part of that popularity stems from improved supply, as GLP-1 shortages ended for tirzepatide in December 2024 and for semaglutide in February 2025. Some patients may also be prescribed compounded semaglutide or compounded tirzepatide in patient-specif
